Yttrium 90-radiolabelled OTSA 101 - OncoTherapy Science
Alternative Names: Frizzled homologue 10 antibodies - OncoTherapy Science; Frizzled-10 antibodies - OncoTherapy Science; Fz-10 antibodies - OncoTherapy Science; FZD10 monoclonal antibodies - OncoTherapy Science; hFz10 antibodies - OncoTherapy Science; OTSA 101 DTPA-90Y; OTSA101; TT641 pAb - OncoTherapy ScienceLatest Information Update: 13 Jul 2023
At a glance
- Originator OncoTherapy Science
- Developer Centre Leon Berard; OncoTherapy Science
- Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals; Radiosensitisers
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Synovial sarcoma
Most Recent Events
- 13 Jul 2023 Discontinued - Phase-I for Synovial sarcoma(Inoperable/unresectable, Second-line therapy or greater) in France (IV), prior to March 2023 (OncoTherapy Science pipeline, July 2023)
- 31 Mar 2023 Yttrium 90-radiolabelled OTSA 101 is still in phase I trials for Synovial-sarcoma (Refractory metastatic disease, Second-line therapy or greater) in Japan (IV, Injection) (NCT04176016) (OncoTherapy Science pipeline, July 2023)
- 11 Sep 2020 No development reported - Phase-I for Synovial sarcoma in France (IV) (OncoTherapy science pipeline September 2020)